Pre-transplant risk factors affecting outcome in Hurler syndrome. (Q51800411)

12 April 2018

title

Pre-transplant risk factors affecting outcome in Hurler syndrome. (English)

1 reference

12 April 2018

author

Jakub Tolar

9

1 reference

12 April 2018

Bruce R Blazar

6

object named as

B R Blazar

1 reference

12 April 2018

P J Orchard

1

1 reference

12 April 2018

C Milla

2

1 reference

12 April 2018

E Braunlin

3

1 reference

12 April 2018

T DeFor

4

1 reference

12 April 2018

K Bjoraker

5

1 reference

12 April 2018

C Peters

7

1 reference

12 April 2018

J Wagner

8

1 reference

12 April 2018

language of work or name

English

0 references

publication date

9 November 2009

1 reference

12 April 2018

Bone Marrow Transplantation

published in

1 reference

12 April 2018

volume

45

1 reference

12 April 2018

page(s)

1239-1246

1 reference

12 April 2018

issue

7

1 reference

12 April 2018

https://scigraph.springernature.com/pub.10.1038/bmt.2009.319

exact match

0 references

cites work

The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Mucopolysaccharidosis I: management and treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Laronidase treatment of mucopolysaccharidosis I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Cord-blood transplants from unrelated donors in patients with Hurler's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Trends in haematopoietic cell transplantation for inborn errors of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation in patients with inherited metabolic storage disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Life-threatening pulmonary hemorrhages post bone marrow transplantation in Hurler syndrome. Report of three cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Pre-stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post-transplant: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

The clinical outcome of Hurler syndrome after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Children with mucopolysaccharidosis: perioperative care, morbidity, mortality, and new findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

The mucopolysaccharidoses and anaesthesia: a report of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Autopsy findings in umbilical cord blood transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

7 January 2021

Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

7 January 2021

Anaesthetic implications of the mucopolysaccharidoses: a fifteen-year experience in a children's hospital.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

7 January 2021

Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.319

7 January 2021

Identifiers

DOI

10.1038/BMT.2009.319

1 reference

12 April 2018

PubMed ID

19898501

1 reference

12 April 2018